These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7980759)

  • 1. Roxithromycin and lower respiratory tract infections.
    Scott WG; Cooper BC; Scott HM; Karalus NC; Garrett J; Lang SD
    N Z Med J; 1994 May; 107(978):208. PubMed ID: 7980759
    [No Abstract]   [Full Text] [Related]  

  • 2. Roxithromycin vs amoxycillin/clavulanic acid in lower respiratory tract infections.
    Brett W
    N Z Med J; 1994 Aug; 107(983):319-20. PubMed ID: 8052477
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of roxithromycin versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study.
    Scott WG; Cooper BC; Scott HM
    Infection; 1995; 23 Suppl 1():S21-4. PubMed ID: 7782111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roxithromycin versus amoxicillin-clavulanic acid in the treatment of respiratory tract infections.
    Lousbergh D; Jochems G; Everaert L; Puttemans M
    Diagn Microbiol Infect Dis; 1992; 15(4 Suppl):91S-95S. PubMed ID: 1617931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
    Lim TK
    Singapore Med J; 1997 Mar; 38(3):139. PubMed ID: 9269388
    [No Abstract]   [Full Text] [Related]  

  • 6. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice.
    Karalus NC; Garrett JE; Lang SD; Leng RA; Kostalas GN; Cursons RT; Cooper BC; Ryan CJ
    Infection; 1995; 23 Suppl 1():S15-20. PubMed ID: 7782110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antibiotic prophylaxis of wound infection.
    Davey PG
    J Chemother; 1994 Apr; 6 Suppl 2():29-33. PubMed ID: 7799052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Augmentin--current and prospective therapeutic indications].
    Mihălţan F
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1988; 37(3):203-10. PubMed ID: 2855664
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of pulmonary bacterial infections with amoxicillin and clavulanic acid: clinical experience].
    Bisetti A; Grassi L; Romano V; Scacciavillani E
    Arch Monaldi Mal Torace; 1987; 42(6):505-17. PubMed ID: 3334114
    [No Abstract]   [Full Text] [Related]  

  • 11. [Usefulness of an amoxicillin/clavulanic-acid combination in respiratory tract infection: bacterial resistance and antibiotic therapy].
    Caramia M; Taddei G; Nobilini A
    Minerva Pediatr; 1990; 42(1-2):29-34. PubMed ID: 2186263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of amoxicillin and amoxiclav in the therapy of respiratory infections].
    Music E; Kumelj M; Prlja D; Paulin A; Potokar T
    Plucne Bolesti; 1989; 41(3-4):187-92. PubMed ID: 2636405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of infective respiratory diseases with a shielded beta-lactam antibiotic (amoxicillin and clavulanic acid)].
    Palermo B; Rizza S; Pistorio MP; Crimi N; Maccarrone C; Mistretta A
    Arch Monaldi Mal Torace; 1987; 42(6):519-33. PubMed ID: 3334115
    [No Abstract]   [Full Text] [Related]  

  • 14. Augmentin for urinary tract infections.
    Bailey RR
    N Z Med J; 1992 Mar; 105(929):90. PubMed ID: 1545949
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections.
    Dautzenberg B; Scheimberg A; Brambilla C; Camus P; Godard P; Guerin JC; Lemarie E; Rezvani Y; Rosembaum M; Tuchais E
    Diagn Microbiol Infect Dis; 1992; 15(4 Suppl):85S-89S. PubMed ID: 1617930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clavulanic acid-shielded amoxicillin in the treatment of acute and chronic infective diseases of the pulmonary system].
    Micillo E; Dericoloso A; Tranchese D; Cione P
    Arch Monaldi Mal Torace; 1987; 42(6):535-49. PubMed ID: 3334116
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of twice-daily amoxycillin/clavulanate ('Augmentin-Duo' 400/57) in mild to moderate lower respiratory tract infection in children.
    Cook RC; Zachariah J; Cree F; Harrison HE
    Br J Clin Pract; 1996; 50(3):125-8. PubMed ID: 8733329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative research on Augmentin].
    Robinson OP
    Antibiot Khimioter; 1992 Sep; 37(9):9-11. PubMed ID: 1444674
    [No Abstract]   [Full Text] [Related]  

  • 20. A pharmacoeconomic comparison of amoxicillin/clavulanate and cefpodoxime proxetil in the treatment of acute otitis media.
    Landholt TF; Kotschwar TR
    Clin Ther; 1994; 16(2):327-33; discussion 271-2. PubMed ID: 8062326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.